Waverley Biotech

Waverley Pharma is a Canadian biopharmaceutical company focused on the development and commercialization of oncology therapeutics. Headquartered in Winnipeg, the company employs a dual-track strategy that combines the development of a proprietary PARP-1 inhibitor program with the commercialization of generic oncology injectables in international markets. Through a key partnership with Reliance Life Sciences, Waverley Pharma has successfully launched generic versions of bortezomib, pemetrexed, and capecitabine in the United Kingdom and Germany. The company is also active in the United States, having recently acquired C & R Pharmacy to expand its pharmaceutical services. Waverley Pharma is publicly traded on the TSX Venture Exchange under the symbol WAVE and continues to seek opportunities to provide affordable and effective cancer treatments.